Loading…

Loading grant details…

Completed NON-SBIR/STTR RPGS NIH (US)

Targeting Atg5 in platinum-resistant ovarian cancer

$2.12M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization Wayne State University
Country United States
Start Date Jan 01, 2021
End Date Dec 31, 2023
Duration 1,094 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10307116
Grant Description

Abstract Ovarian cancer is the fifth leading cause of cancer-related death in the United States. The standard first line chemotherapy to treat this deadly disease includes platinum (cisplatin/carboplatin)-based treatment, but the development of drug resistance presents a significant clinical problem that needs to be addressed.

Our current study identifies a novel mechanism of cisplatin resistance involving autophagy-related gene (Atg) 5. Atg5 is a member of the Atg family that plays an important role in regulating autophagy, a process essential for the quality control of cellular components under various stress conditions. Previous studies

showed that the inhibition of autophagy sensitizes cancer cells to chemotherapy. Our own study showed that the blockade of autophagy induction promotes cisplatin sensitivity in human ovarian cancer cells, but strategies for targeting autophagy in cancer therapies in general are not well developed. We find that Atg5

is overexpressed in human ovarian tumors, and that its overexpression inhibits cisplatin-induced apoptosis in ovarian cancer cells. We also find that Atg5 overexpression is correlated with the poor overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Additionally, we find that

Atg5 is phosphorylated but the effects of its phosphorylation on Atg5-mediated autophagy and cisplatin resistance remain to be determined. Based on these novel observations, we hypothesize that elevated Atg5 expression confers growth advantage of ovarian cancer cells by promoting cell survival and drug

resistance. The objectives of this project are to define the role of Atg5 in cisplatin resistance and the impact of Atg5 phosphorylation on cisplatin resistance. These objectives will be achieved by the following two Specific Aims: 1) Define the role of Atg5 in cisplatin resistance both in vitro and in vivo using ovarian

cancer mouse models; and 2) Determine the regulation of Atg5 phosphorylation and its impact on cisplatin resistance. Successful results from this study could lead to the development of novel therapeutic strategies for treating ovarian cancer patients.

All Grantees

Wayne State University

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant